- Paper accepted in Dermatology and Therapy, a peer-reviewed journal.
- Paper introduces QRX003 mechanism of action in Netherton Syndrome.
- Case report: pediatric patient achieved fully healed skin, no itch, no sleep disturbances, reduced medications.
- No approved therapies for Netherton Syndrome in the US.
- Quoin Pharmaceuticals announced that a peer-reviewed manuscript on QRX003 has been accepted for publication in Dermatology and Therapy. The paper introduces the drug's mechanism of action in Netherton Syndrome and includes a pediatric compassionate-use case report showing fully healed skin, no itch, no sleep disturbances, and reduced medication needs.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card